Plain-English translation of NCT07655622 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether two medications taken together— and furmonertinib—can work better than existing treatments for people with advanced lung cancer that has specific genetic mutations (EGFR mutations) and high PD-L1 expression. The trial is designed in two phases: first to find the right dose, then to see if this combination can help patients live longer before their cancer grows.
People with this specific type of advanced lung cancer often don't respond well to standard single-drug treatments, with the cancer typically starting to grow again after just a few months. This trial aims to overcome that resistance by blocking two different pathways in the cancer cells at the same time, potentially helping patients stay healthier for much longer.
You likely qualify if…
You likely don't qualify if…
You would take both medications by mouth daily as a first-line treatment for your cancer. The trial has two phases: in Phase 1, researchers gradually increase the dose in small groups of patients to find the safest and most effective dose; in Phase 2, more patients receive the chosen dose. You will have imaging scans every 8 weeks to check how your cancer is responding, along with regular blood tests, heart rhythm checks, and heart ultrasounds to monitor your safety. Treatment continues until your cancer progresses, side effects become too severe, or you choose to stop.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China